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A B S T R A C T
Scintigraphy with Tc-99m dimercaptosuccinic acid (DMSA) is considered a reference method for assessment of
parenchymal lesions and estimation of differential kidney function. The aim of study was to evaluate Tc-99m mer-
captoacetyltriglycine (MAG3) dynamic renal scintigraphy for the same purpose. 188 patients, submitted to both stud-
ies within three months, were divided in two groups. In the first, 83 DMSA images were compared to parenchymal
phase of MAG3 scintigraphy. Kidney morphology was independently evaluated by four observers. In the second group
(N=105), differential function was calculated in MAG3 and DMSA studies and the respective results were compared.
Findings corresponded completely in 85% of patients. There were no statistically significant differences between calcu-
lated differential function on DMSA and MAG3 images. The results showed that most of parenchymal lesions detected
on DMSA scans can be identified on MAG3 parenchymal scans. Both studies can be equally used for the calculation of
differential kidney function.
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Introduction
Functional and morphological investigations with
radionuclides play a prominent role in the diagnostics
and follow up of various kidney diseases1,2. Tc-99m
mercaptoacetyltriglycine (MAG3) scintigraphy has been
used for that purpose for more than ten years3–10.
Tc-99m dimercaptosuccinic acid (DMSA) scintigraphy
has been considered the investigation of choice in the
assessment of renal cortical lesions11 for almost 30
years. Other non-invasive procedures such as intrave-
nous urography (IVU) and ultrasound (US) are consid-
ered less sensitive in detection of cortical lesions12–18,
the former at the same time delivering higher radiation
dose19. Computed tomography (CT) has sensitivity and
specificity similar to those of cortical scintigraphy for
the detection of acute pyelonephritis but, carries the
risk of contrast reaction and has a considerably higher
radiation exposure, as well. Magnetic resonance imag-
ing is a promising but expensive and not widely avail-
able nonionizing method of visualizing pyelonephritis20.
Dynamic scintigraphy with MAG3 gives an insight
in kidney function and morphology21–23. The initial part
of the study, the parenchymal phase, reflects the distri-
bution of functional parenchyma, allowing the detection
of reversible or irreversible lesions. Some authors still
consider the evaluation of the renal parenchyma with
MAG3 in only one-posterior-projection less reliable than
DMSA, where multiple projections are available24,25. On
the other hand, DMSA provides no information about
the collecting system and urodynamics, and in compari-
son with MAG3, delivers higher radiation dose.
DMSA scintigraphy is also generally accepted proce-
dure for estimation of differential kidney function, but
from recently, MAG3 has been introduced for the same
purpose26,27.
The objective of this paper was to examine the reli-
ability of renal parenchyma evaluation and calculation
of differential renal function with MAG3 in comparison
to DMSA.
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Patients and Methods
Between January 1988 and December 2002, 188 pa-
tients who had undergone DMSA and MAG3 scinti-
graphy within 3 months as part of their clinical workup
at the University Hospital Centre Rijeka, were selected
for this retrospective study. They were referred by neph-
rologists, urologists and/or pediatric nephrologists.
DMSA study had been requested first when cortical
lesions were suspected in patents with urinary tract in-
fection. MAG3 was additionally performed when find-
ings were equivocal or when the need for more informa-
tion on function and/or urodinamics appeared. When
patients had been referred firstly to MAG3 dynamic
scintigraphy and a parenchymal lesion was found,
DMSA was performed to confirm or exclude the lesion.
The first group, where parenchymal images were an-
alyzed, included 83 patients (57 females, 26 males,
mean age 34.5 years, range 2–81 years), 34 of them were
children (14 under 7 yrs, 20 between 7 and 15 yrs, mean
age 7 years).
The second group, for purposes of differential func-
tion calculation, included another 105 patients, 55 of
them children under 15 years of age (19 under 7 yrs., 36
between 7 and 15 yrs, mean age 6.5 yrs.) and 50 adults
(mean age 38 yrs).
In the population of children (N=89) from both groups,
66 had urinary tract infection including acute and chro-
nic pyelonephritis, half of them with proved vesico-
uretheral reflux. Obstructive or dilatative nephropa-
thies were present in 9 and other diagnoses (mostly
congenital anomalies) in 14 patients.
In the adult population (N=99) 30 patients had uri-
nary tract infection and 13 obstructive or dilatative
nephropathies. Hypertension was present in 26 and
other diagnoses in 30 patients (tumors, cysts, and uni-
lateral poor function).
All patients or their parents were informed about the
diagnostic procedures and gave their written consent.
Data acquisition
DMSA imaging started 2–3 hours after intravenous
injection of 74–100 MBq Tc-99m DMSA. Dose activities
for children were calculated according to the Pediatric
Task Group recommendations28. The lowest activity used
was 18 MBq. Subjects were imaged in standard projec-
tions (posterior, posterior oblique, anterior, and lateral)
with a low-energy, all-purpose collimator, 200 seconds
per view in a 256 x 256 matrix. Only the posterior views
were used for differential function calculation and com-
parison with MAG3.
The dynamic study started immediately after admin-
istration of 2 MBq/kg of Tc-99m MAG3 to a well-hy-
drated subjects. Activities for children were calculated
as mentioned above28; sedation was not used. The data
were acquired with patients lying supine, in a posterior
projection, for 30 min, 30 sec per frame, in a 128 x 128
matrix, using the same equipment. First 3 or 4 frames
summed in a composite parenchymal image were used
for analysis. In cases of poor visualization of paren-
chyma, additional frames were included, thus enabling
better definition of equivocal lesions.
Data analysis
Images were analyzed from a high-resolution moni-
tor capable for gray and eight color scale presentations,
with positive and negative variant. The manual regions
of interest (ROIs) were created tracing kidney contours,
and each was divided in 6 sub regions to make analysis
easier and more accurate (Figure 1).
The distribution of parenchymal activity and out-
lines were interpreted as normal (Figure 2), equivocal or
as a clear lesion.
A renal contour defect with a corresponding photo-
penic area, or a clear »cold area« within renal paren-
chyma, with or without contour defect was defined as a
clear parenchymal lesion (Figure 3). Lesions that did
not meet those criteria were considered equivocal.
All studies were analyzed separately, by four observ-
ers. MAG3 parenchymal phase images were presented to
each observer, for evaluation of parenchymal lesions.
Some time later, posterior DMSA images were presented
to all observers, blinded for the results of the first analy-
sis and the respective clinical data. After that, DMSA
andMAG3 images of the same subject were presented to-
gether for comparison. Two possibilities of interpretation
were offered: no visual difference between the two scans,
and substantial differences in parenchymal distribution
of activity and/or edge definition.
In the second group of patients differential renal func-
tion was calculated according to the standard equation:
LROI / (LROI + RROI) x 100% = DF% of left kidney
Irregular regions of interest were manually drawn
over the left (LROI) and right (RROI) kidney, on DMSA
A. Smokvina et al.: The Renal Parenchyma: MAG3 vs. DMSA, Coll. Antropol. 29 (2005) 2: 649–654
650
Fig. 1. Kidney segments for easier visual interpretation and lo-
calization of parenchymal lesions.
scan in posterior projection and parenchymal phase of
MAG3 study. Summed counts were used for the calcula-
tion in the equation above (Figures 4 and 5).
For the evaluation of differential function (N=105) a
paired t-test and 2 test were used.
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Fig. 3. Multiple clear parenchymal lesions and changes of contours on the DMSA (left) and MAG3 (right) scan in the same patient.
Fig. 4. Normal DMSA (left) and MAG3 (right) scans, regions of interest and calculated differential function in the same patient.
Fig. 2. Normal parenchymal accumulation in both kidneys on the DMSA (left) and MAG3 (right) scan in the same patient.
Results
Correspondence in visual interpretation of paren-
chymal defects with MAG3 and DMSA was present in
85–89% of patients in group I (Table 1).
All observers identified the same 18 kidneys with
clear parenchymal lesions on DMSA scans. Those were
all detected on MAG3 parenchymal scan, as well. Fur-
thermore, two observers detected a greater number of
clear parenchymal lesions on MAG3 scans, which were
interpreted as equivocal on DMSA scan (Table 2). When
clear lesions were detected on MAG3 scan, findings
were never interpreted as normal on DMSA.
The estimated mean difference between split renal
functions calculated from two studies (group II, N=105)
was 0.32.72%, which was not statistically significant (p
> 0.05). In 69 patients (67%) the difference in estimation
of differential function between the two procedures was
<2%. Moreover, in 93% of patients individual kidney
function differed less than 5%.
In the group of patients where the percentage func-
tion of one kidney was abnormal (<45%) there were sig-
nificantly more patients (chi-square = 7.92, p<0.01) with
greater inter-method difference (>2%, Figure 6).
Discussion
This study showed that all clear parenchymal lesions
seen on DMSAwere detected on the parenchymal phase
MAG3 image. There were no statistically significant dif-
ferences between estimated differential kidney function
on DMSA and MAG3, either.
This supports the idea of different approach to nuclear
diagnostic procedures in the underlying field of indicati-
ons. Replacing DMSA with MAG3 in initial assessment
of a patient would provide simultaneous information on
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TABLE 1
COMPLETE VISUAL CORRESPONDENCE BETWEEN DMSA AND
MAG3 SCANS IN THE GROUP I (N=83), INTERPRETED BY 4
OBSERVERS (A–D)
Observer
Patients with complete corres-
pondence between DMSA and
MAG3 scans (group I, N=83)
%
A 74 89
B 71 85
C 73 88
D 74 89
TABLE 2
NUMBER OF PATIENTS WITH CLEAR PARENCHYMAL DEFECTS IN
THE FIRST GROUP I, (N=83), DETECTED BY 4 OBSERVERS (A–D)
Observer
Patients with clear parenchymal lesions
(group I, N=83)
DMSA MAG3
A 18 18
B 18 23
C 18 18
D 18 19
Fig. 5. Parenchymal defects presented in DMSA (left) and MAG3 (right) scans, regions of interest and calculated differential function
in the same patient.
93%
DMSA - MAG3 difference
in split function < 5%
DMSA - MAG3 difference
in split function < 2%
67%
Fig. 6. Difference between differential kidney functions calcu-
lated by two methods (DMSA and MAG3), in the second group
(N=105), in relation to percentage kidney function.
kidney function, drainage and split function, at the
same time lowering the radiation exposure24,30–32.
In clinical practice and treatment, especially during
urinary tract infections, it is important to give an un-
equivocal answer whether clear renal focal lesions do or
do not exist.
Although intravenous urography enables visualizing
of collecting system, and together with ultrasound pro-
vides some information on kidney morphology, quantita-
tive data on kidney function are missing. DMSA scin-
tigraphy is considered the most sensitive method to
prove existence of parenchymal damage due to acute or
chronic pyelonephritis and provides data on differential
kidney function25,29. However, the performances of MAG3
scintigraphy for the same purposes have not been inves-
tigated by many authors24,32.
The first part of study was based on visual interpre-
tation of scans. The major problem of that kind of inter-
pretation is partially due to non-existence of a recog-
nized standard, which can be illustrated by the recent
multicentric study. Among forty- two experienced nu-
clear medicine physicians, who were asked to read 49
DMSA kidney scans, there were even those who clear
parenchymal lesion considered a normal finding33.
It is beyond question that kidney outlines are more
clearly visualized on DMSA scan compared to MAG3,
probably due to different matrices used in the acquisi-
tion of the two studies. However, the quality of MAG3
image can significantly approach DMSAby adding a few
frames to compose the parenchymal phase image.
Additionally, only posterior view available for analy-
sis on MAG3 parenchymal scans might be a problem,
because lesions could potentially be missed. However,
there were no clear parenchymal lesions on DMSA, that
were not visible on MAG3 parenchymal scan and there
were no normal MAG3 scans described as clearly posi-
tive on DMSA, regardless of other projections available
on the latter.
The possibility of visualizing the collecting system
and urodynamics with MAG3, significantly improved
quality of evaluation of kidney parenchyma and reading
of DMSA scans. For example, several photopenic areas
on DMSA and MAG3 parenchymal scans turned out to
be due to dilated parts of the drainage system (calyces),
with retention of activity on MAG3 dynamic scans. That
means that MAG3 is at least as good as DMSA in detect-
ing clear parenchymal lesions and probably even more
specific when dilated parts are present. In the estima-
tion of differential kidney function, there are no differ-
ences between the two radiopharmaceuticals, as well.
Our results support the idea of promoting MAG3 dy-
namic scintigraphy towards the initial nuclear medicine
procedure in the diagnostics of the majority of kidney
diseases. It is specially recommended in the children’s
population, considering lower radiation burden. In cases
where MAG3 shows normal or clearly abnormal find-
ings, the reliable reading can be made from the pa-
renchymal phase scan. DMSA scan could be used for un-
certain or inconclusive MAG3 findings only.
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PROCJENA BUBRE@NOG PARENHIMA: MAG3 vs. DMSA
S A @ E T A K
Scintigrafija tehnecijem obilje`enom dimerkaptosukcini~nom kiselinom (DMSA), smatra se referentnom meto-
dom za otkrivanje parenhimskih lezija i odre|ivanje diferencijalne funkcije bubrega. Cilj studije je bio da se istra`i
upotreba tehnecijem obilje`enog merkaptoacetiltriglicina (MAG3) u iste svrhe. Pacijenti, kojima su obje studije bile
u~injene unutar 3 mjeseca (N=188), bili su podijeljeni u dvije grupe. U prvoj je 83 scintigrama u~injenih sa DMSA
uspore|eno sa parenhimskom fazom studije sa MAG3. Morfologiju bubrega su procjenjivala ~etiri ispitiva~a. Nalazi
su se podudarali u 85 % pacijenata. U drugoj grupi (N=105) su uspore|ene vrijednosti diferencijalne funkcije bubrega
dobivene pomo}u dva radiofarmaka (DMSA i MAG3). Nisu na|ene statisti~ki zna~ajne razlike izme|u vrijednosti
dobivenih pomo}u dvije metode. Rezultati su pokazali da se ve}ina lezija koje se otkriju na scintigrafiji sa DMSA,
mo`e vidjeti i na scintigramima parenhimske faze sa MAG3, te da se obje studije mogu jednako upotrijebiti za odre-
|ivanje diferencijalne funkcije bubrega.
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